GlassScriptPhysician profile
Jeffrey D'Alessandro
NPI 1275061954
$1,878.21
in general payments reported to CMS, 2019-2025
14 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.13 · 2021: $558 · 2022: $239 · 2023: $73.57 · 2024: $711 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763 · Travel and Lodging: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.27 |
| Travel and Lodging | $296.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $543.13 | 2021-2022 | |
| Mimedx Group, INC. | $288.72 | 2024-2025 | |
| Stryker Corporation | $255.68 | 2024 | Salvation |
| Treace Medical Concepts, INC. | $176.83 | 2023-2024 | |
| Shockwave Medical, INC | $174.25 | 2025 | |
| Zimmer Biomet Holdings, INC. | $150.00 | 2021 | |
| Abbvie INC. | $109.02 | 2021-2024 | Dalvance, Teflaro |
| Grt US Holding, INC. | $44.53 | 2020-2021 | |
| Averitas Pharma INC. | $34.07 | 2025 | Qutenza |
| Tactile Systems Technology INC | $33.14 | 2021 | |
| Integra Lifesciences Corporation | $20.85 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Pacira Pharmaceuticals Incorporated | $19.51 | 2021 | |
| Kerecis Limited | $14.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Amgen INC. | $14.18 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey D'Alessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.